I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.

Leave site
Roche and Genentech at

AAN 2026

We will be contributing to topics related to
-
08:54 PM
Duration 15mins Chicago, USA
Preservation of Ambulation and Hand Function at Healthy-Control Levels With First-Line Treatment With Ocrelizumab: Six-Year Findings From the ENSEMBLE Trial
Robert A Bermel, Ralph HB Benedict, Thomas Berger, Ludo Vanopdenbosch, Trygve Holmoy, Suzanne Moore, Licinio Craveiro, Joep Killestein
04:45 PM
Duration 60mins Chicago, USA
Beyond motor function in adults with spinal muscular atrophy (SMA): A systematic literature review of real-world outcomes with risdiplam
Carol Jean Guittari
Duration 60mins Chicago, USA
Real-world motor function outcomes with risdiplam in Types 2 and 3 SMA: A systematic literature review and meta-analysis
Carol Jean Guittari
Duration 30mins Chicago, USA
Patients' Knowledge and Attitudes Toward Serum Neurofilament Light Chain Testing in Early-stage Relapsing-remitting Multiple Sclerosis
Elena García-Arcelay, Inés González-Suárez, Jacobo Caruncho, Antonio Candeliere-Merlicco, Aida Orviz, Jesús Martín-Martínez, Raquel Piñar, Elena Álvarez-Rodríguez, Eva Pacheco, Laura Borrega, Ignacio Casanova, Ana B Caminero, José L Sánchez-Menoyo, Montserrat Gómez-Gutiérrez, Olga Carmona, Carmen Calles, Miguel A Hernández, Pablo López-Muñoz, Jorge Mauriño, Ángel Pérez-Sempere
10:00 PM
Duration 30mins Chicago, USA
OUTSMARTING THERAPEUTIC INERTIA: CAN CHATGPT-4O BEAT NEUROLOGISTS IN MULTIPLE SCLEROSIS AND NEUROMYELITIS OPTICA SPECTRUM DISORDER CARE?
Elena García-Arcelay, Rocío Gómez-Ballesteros, Aleix Solanes, Enric Monreal, María Sepúlveda, Ángel Pérez Sempere, Miguel Ángel Hernández, Juan Pablo Cuello, Gary Álvarez-Bravo, Eduardo Agüera, Javier Riancho, Jorge Maurino, Gustavo Saposnik
01:00 PM
Duration 60mins Chicago, USA
Week 96 Analysis of the OCARINA II Study Characterizing Subcutaneous Ocrelizumab in Patients With Relapsing or Primary Progressive Multiple Sclerosis
Caroline Giacobino, Catarina Figueiredo, Diego Centonze, Dusanka Zecevic, Eva Krzystanek, Jay Azmi, Krzysztof Selmaj, Lawrence Goldstick, Scott Newsome, Susanne Clinch
03:30 PM
Duration 15mins Chicago, USA
Safety and efficacy of satralizumab in patients with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): Results from the phase 3 METEOROID trial
Michael Levy, Eoin P. Flanagan, Tania Kümpfel, Romain Marignier, Kazuo Fujihara, Cheryl Hemingway, Daniela Stokmaier, Gaëlle Klingelschmitt, H.-Christian von Büdingen, Li Li, Sayuri Tanaka, Friedemann Paul
11:09 PM
Duration 15mins Chicago, USA
Efficacy and Safety of Fenebrutinib vs Teriflunomide in Relapsing Multiple Sclerosis: Results of the FENhance 1 and 2 Studies
Oh, Jiwon; Bar-Or, Amit; Giovannoni, Gavin; Sormani, Maria Pia; Weber, Martin S.; Stoll, Sharon; Nicholas, Jacqueline A.; von Büdingen, H. -Christian; Decker-Palmer, Marquita; Loukitcheva, Anastasia; Triyatni, Miriam; Hu, Nan; Ratchford, John N.; Napieralski, Julie; Goodyear, Alexandra; Kappos, Ludwig; Hauser, Stephen L.
06:00 PM
Duration 15mins Chicago, USA
ORATORIO-HAND: Results of the Primary Analysis of Ocrelizumab vs Placebo in Primary Progressive Multiple Sclerosis, Including Older Patients and Those With More Advanced Disease
Jiwon Oh, Gavin Giovannoni, Laura Airas, Riley Bove, Gary R Cutter, Jeremy Hobart,​ Jens Kuhle, Xavier Montalban, Carmen Tur, Jerry S Wolinsky, Hans-Martin Schneble, ​Anna Baldinotti, Ulrike Bonati, Caroline Giacobino, Qing Wang, Ke Yang
06:12 PM
Duration 15mins Chicago, USA
Humoral Vaccine Responses and 1-Year Follow-Up of Infants Potentially Exposed to Ocrelizumab During Pregnancy and Breastfeeding: Final Analyses of the Prospective, Multicenter, Open-Label, Phase IV Studies MINORE and SOPRANINO
Agne Kazlauskaite, Anna Shah, Celia Oreja Guevara, Carlo Pietrasanta, Daniela Goncalves Pereira Alves, Dina Jacobs, Edith Graham, Elisabeth Maillart, Riley Bove, Ruth Dobson, Sandra Vukusic, Thomas McElrath, Tobias Derfuss
06:36 PM
Duration 15mins Chicago, USA
Efficacy and Safety of Fenebrutinib vs Ocrelizumab in Primary Progressive Multiple Sclerosis: Primary Results of the Phase III FENtrepid Study
Bar-Or, Amit; Oh, Jiwon; Giovannoni, Gavin; Sormani, Maria Pia; Weber, Martin S; Stoll, Sharon; Nicholas, Jacqueline A; von Büdingen, H.-Christian; Lopez, Jon; Roberts, Louise; Triyatni, Miriam; Qi, Qi; Ratchford, Jack; Napieralski, Julie; Goodyear, Alexandra; Hauser, Stephen L; Kappos, Ludwig
06:48 PM
Duration 15mins Chicago, USA
Efficacy and Safety of Ocrelizumab Compared With Fingolimod in Pediatric-Onset Relapsing-Remitting MS: Results of the Phase III OPERETTA 2 Study
Brenda Banwell, Katarzyna Kotulska, Kevin Rostásy, Kumaran Deiva, Henry Sato, Massimo Filippi, Tanuja Chitnis, Maria Pia Sormani, Lauren Krupp, Amit Bar-Or, Joanna Evershed, Bouchra El Azzouzi, Qing Wang, Chien-Ju Lin, Alexandra Hogea, Hans-Martin Schneble, Corinne Manlius, Emmanuelle Waubant
Coming soon